Lineage Cell Obtains CE Mark for Facial Lipoatrophy Treatment

Lineage Cell Therapeutics received the CE Mark for its Renevia resorbable matrix, a Class III device used in treating facial lipoatrophy.

The device has been cleared as a resorbable matrix for delivering autologous adipose tissue preparations to restore or augment facial volume in adults following subcutaneous fat volume loss.

The product is designed to mimic the naturally occurring extracellular matrix in the body and provide a 3-D scaffold, which supports effective adipose tissue transplant, retention, engraftment, and metabolic support, the company said.